Exploring manzamine a: a promising anti-lung cancer agent from marine sponge Haliclona sp DOI Creative Commons

Su Min,

Jie Zhu, Lu Bai

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 25, 2025

Manzamine A (MA), a bioactive compound derived from the marine sponge Haliclona sp., shows considerable therapeutic potential, particularly in treatment of various cancer types. Extracted with acetone and purified through chromatography, MA exhibits bioavailability 20.6% when administered orally rats, underscoring its feasibility for use. This disrupts key cellular mechanisms essential progression, including microtubule dynamics DNA replication enzymes, demonstrating strong anti-proliferative effects against multiple cell lines while sparing normal cells. Additionally, network pharmacology molecular docking studies reveal MA's interactions important targets related to lung such as EGFR SRC, bolstering potential novel anti-lung agent. Pathway analyses further indicate that influences critical signaling pathways involved tumor growth metastasis. Given urgent need effective treatments drug-resistant cancers limited toxicity profile MA, exploration pharmacological benefits mechanism could pave way new strategies cancer.

Language: Английский

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges DOI Creative Commons

Yuchu Xiang,

Xudong Liu, Yifan Wang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: April 9, 2024

Resistance to targeted therapy and immunotherapy in non-small cell lung cancer (NSCLC) is a significant challenge the treatment of this disease. The mechanisms resistance are multifactorial include molecular target alterations activation alternative pathways, tumor heterogeneity microenvironment change, immune evasion, immunosuppression. Promising strategies for overcoming development combination therapies, understanding better use novel drug targets, identification biomarkers, modulation so on. Ongoing research into new therapeutic approaches hold great promise improving outcomes patients with NSCLC. Here, we summarize diverse driving NSCLC latest potential promising overcome help who suffer from

Language: Английский

Citations

26
Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies DOI
Disha D. Shah, Mehul R. Chorawala, Neha R. Raghani

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(4)

Published: March 18, 2025

Language: Английский

Citations

3
Nanomedicine Combats Drug Resistance in Lung Cancer DOI
Xiuli Zheng, Xiao-Hai Song,

Guonian Zhu

et al.

Advanced Materials, Journal Year: 2023, Volume and Issue: 36(3)

Published: Nov. 16, 2023

Lung cancer is the second most prevalent and leading cause of cancer-related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, radiotherapy are currently available as treatment methods. However, drug resistance a significant factor in failure lung treatments. Novel therapeutics have been exploited to address complicated mechanisms advancement nanomedicine extremely promising terms overcoming resistance. Nanomedicine equipped with multifunctional tunable physiochemical properties alignment tumor genetic profiles can achieve precise, safe, effective while minimizing or eradicating cancer. Here, this work reviews discovered for radiotherapy, outlines novel strategies development against This focuses on engineering design, customized delivery, current challenges, clinical translation application resistant

Language: Английский

Citations

36
Activities against Lung Cancer of Biosynthesized Silver Nanoparticles: A Review DOI Creative Commons
Jorge L. Mejía-Méndez, Edgar R. López-Mena, Eugenio Sánchez-Arreola

et al.

Biomedicines, Journal Year: 2023, Volume and Issue: 11(2), P. 389 - 389

Published: Jan. 28, 2023

Nanomedicine is an interdisciplinary field where nanostructured objects are applied to treat or diagnose disease. Nanoparticles (NPs) a special class of materials at nanometric scale that can be prepared from lipids, polymers, noble metals through bottom-up approaches. Biological synthesis reliable, sustainable, and non-toxic method uses phytochemicals, microorganisms, enzymes induce the reduction metal ions into NPs. Silver (Ag) NPs exhibit potent therapeutic properties exploited overcome limitations current treatment modalities for human health issues such as lung cancer (LC). Here, we review preparation AgNPs using biological their application against LC in vitro vivo models. An overview staging, diagnosis, genetic mutations, LC, well its main subtypes, presented. A summary reaction mechanisms microbial cell cultures, plant extracts, amino acids included. The use capping agents biosynthesis with anticancer activity also detailed. history activities metal-based nanostructures synthesized gold, copper, palladium, platinum considered. possible models covered. Our perspective about future nanomedicine added.

Language: Английский

Citations

23
Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions DOI Open Access
Pankaj Garg, Sulabh Singhal, Prakash Kulkarni

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(14), P. 4189 - 4189

Published: July 18, 2024

The leading cause of cancer deaths worldwide is attributed to non-small cell lung (NSCLC), necessitating a continual focus on improving the diagnosis and treatment this disease. In review, latest breakthroughs emerging trends in managing NSCLC are highlighted. Major advancements diagnostic methods, including better imaging technologies utilization molecular biomarkers, discussed. These have greatly enhanced early detection personalized plans. Significant improvements patient outcomes been achieved by new targeted therapies immunotherapies, providing hope for individuals with advanced NSCLC. This review discusses persistent challenges accessing treatments their associated costs despite recent progress. Promising research into therapies, such as CAR-T therapy oncolytic viruses, which could further revolutionize treatment, also aims inform inspire continued efforts improve patients globally, offering comprehensive overview current state future possibilities.

Language: Английский

Citations

14
Nanozymes with biomimetically designed properties for cancer treatment DOI Creative Commons
Ke Xu, Yujie Cui, Bin Guan

et al.

Nanoscale, Journal Year: 2024, Volume and Issue: 16(16), P. 7786 - 7824

Published: Jan. 1, 2024

The therapeutic efficacy of nanozymes, which have wide applications in cancer treatment, can be enhanced by various biomimetic design strategies, from structural and process mimicry to advanced functional biomimicry.

Language: Английский

Citations

11
PPARγ Modulators in Lung Cancer: Molecular Mechanisms, Clinical Prospects, and Challenges DOI Creative Commons
Jiyun Zhang,

Miru Tang,

Jinsai Shang

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(2), P. 190 - 190

Published: Feb. 4, 2024

Lung cancer is one of the most lethal malignancies worldwide. Peroxisome proliferator-activated receptor gamma (PPARγ, NR1C3) a ligand-activated transcriptional factor that governs expression genes involved in glucolipid metabolism, energy homeostasis, cell differentiation, and inflammation. Multiple studies have demonstrated PPARγ activation exerts anti-tumor effects lung through regulation lipid induction apoptosis, cycle arrest, as well inhibition invasion migration. Interestingly, may pro-tumor on cells tumor microenvironment, especially myeloid cells. Recent clinical data has substantiated potential agonists therapeutic agents for cancer. Additionally, also show synergistic with traditional chemotherapy radiotherapy. However, application remains limited due to presence adverse side effects. Thus, further research trials are necessary comprehensively explore actions both stromal evaluate vivo toxicity. This review aims consolidate molecular mechanism modulators discuss their prospects challenges tackling

Language: Английский

Citations

10
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance DOI

Kumarappan Chidambaram,

Arcot Rekha, Ahsas Goyal

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155954 - 155954

Published: April 1, 2025

Language: Английский

Citations

1
Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment DOI Creative Commons
Mahesh Koirala,

Mario DiPaola

Biomedicines, Journal Year: 2024, Volume and Issue: 12(8), P. 1801 - 1801

Published: Aug. 8, 2024

Resistance to cancer drugs is a complex phenomenon that poses significant challenge in the treatment of various malignancies. This review comprehensively explores resistance mechanisms and discusses emerging strategies modalities overcome this obstacle. Many factors contribute resistance, including genetic mutations, activation alternative signaling pathways, alterations tumor microenvironment. Innovative approaches, such as targeted protein degradation, immunotherapy combinations, precision medicine, novel drug delivery systems, hold promise for improving outcomes. Understanding intricacies leveraging innovative are essential advancing therapy.

Language: Английский

Citations

8
Social and Biological Determinants in Lung Cancer Disparity DOI Open Access
Briana A. Brock, Hina Mir,

Eric L. Flenaugh

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(3), P. 612 - 612

Published: Jan. 31, 2024

Lung cancer remains a leading cause of death in the United States and globally, despite progress treatment screening efforts. While mortality rates have decreased recent years, long-term survival patients with lung continues to be challenge. Notably, African American (AA) men experience significant disparities compared European Americans (EA) terms incidence, treatment, survival. Previous studies explored factors such as smoking patterns complex social determinants, including socioeconomic status, personal beliefs, systemic racism, indicating their role these disparities. In addition factors, emerging evidence points variations tumor biology, immunity, comorbid conditions contributing racial this disease. This review emphasizes differences patterns, screening, early detection intricate interplay social, biological, environmental that make more susceptible developing experiencing poorer outcomes.

Language: Английский

Citations

7